Evolent Health, Inc. current report, 08 August 2017

Full document

Evolent Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Evolent Health, Inc. on August 8, 2017, regarding an event reported on that date. The Company, a Delaware corporation, entered into a material definitive agreement for an underwritten public offering of its Class A common stock.

Key Financial Metrics

  • Shares Offered: 8,816,120 shares of Class A common stock.
  • Over-Allotment Option: Underwriters hold a 30-day option to purchase up to 1,322,418 additional shares.
  • Estimated Net Proceeds: Approximately $166.8 million after underwriting discounts, commissions, and offering expenses.
  • Use of Proceeds: Working capital, general corporate purposes, business expansion, acquisitions, and investments.
  • Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

The primary material change is the execution of the Underwriting Agreement with J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC. The offering closed on August 14, 2017. Net proceeds were transferred to the operating subsidiary, Evolent Health LLC.

Outlook, Risks, and Management Commentary

Management intends to utilize the capital raised to expand the business through acquisitions and investments. The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification provisions. The offering was conducted pursuant to a registration statement on Form S-3ASR (File No. 333-219755) which became effective on August 7, 2017.

Investor Verification Checklist

  • Verify the final closing price per share and total gross proceeds in the final prospectus supplement.
  • Confirm whether the underwriters exercised the 30-day over-allotment option for the additional 1,322,418 shares.
  • Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification details.
  • Monitor subsequent filings for the actual allocation of proceeds toward acquisitions or investments.